Sunday, July 5, 2015

First Generic Lipitor Approved

0 comments

THURSDAY, Dec. 1 (HealthDay News) -- The first generic version of the cholesterol-lowering statin Lipitor (atorvastatin calcium) has been approved by the U.S. Food and Drug Administration.

Drug maker Ranbaxy Laboratories, based in India, has gained approval to produce the tablets in 10 milligram (mg), 20 mg, 40 mg and 80 mg strengths, the FDA said in a news release. The agency stressed that makers of generic drugs are required to pass the same production- and packaging-quality standards as producers of brand-name drugs.

People with above-normal levels of low-density lipoprotein (LDL, the so-called "bad" cholesterol), are at greater risk of heart attack and stroke when LDL levels build up in the arteries and inhibit blood flow. Lipitor blocks an enzyme in the liver, helping to lower levels of LDL and another form of blood cholesterol, triglycerides.

In clinical trials for the brand-name Lipitor, produced by Pfizer, the most common side effects included nasal inflammation, joint pain, diarrhea and urinary tract infection.

More information

To learn more about this approval, visit the FDA.


-- Scott Roberts

Array

Copyright © 2011 HealthDay. All rights reserved.
0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
Latest Health Videos
Also on Philly.com:
letter icon Newsletter